[Inflammaging: the signaling role of p65 protein from the NF-κB family.].

Inflamaging is a chronic, low-grade inflammation that occurs due to a disruption in the regulation of the immune system during the aging process. This condition is associated with an increased risk of age-related illnesses, such as cardiovascular disease, neurodegenerative conditions, and metabolic disorders. Transcription factor NF-κB is one of the primary regulators of innate and adaptive immune responses, and its activation leads to the production of pro-inflammatory cytokines and chemokines that contribute to inflamaging.

[Experience in the use of cladribine for the treatment of patients with highly active forms of multiple sclerosis in the Moscow region].

Objective: To assess the efficacy and safety of cladribine in patients with highly active multiple sclerosis (MS) in the Moscow region.

Material And Methods: The analysis was based on data from 62 patients treated with cladribine between March 2021 and January 2024. The diagnosis of VAMS was confirmed in 51 patients, PPMS in 4 patients, and SPMS with exacerbations was diagnosed in 7 cases.

Open Genes-a new comprehensive database of human genes associated with aging and longevity.

The Open Genes database was created to enhance and simplify the search for potential aging therapy targets. We collected data on 2402 genes associated with aging and developed convenient tools for searching and comparing gene features. A comprehensive description of genes has been provided, including lifespan-extending interventions, age-related changes, longevity associations, gene evolution, associations with diseases and hallmarks of aging, and functions of gene products.

[The use of monoclonal antibodies in the treatment of patients with high-active multiple sclerosis in real clinical practice].

Objective: To study the efficacy of ocrelizumab (OCR) and natalizumab (NAT) using indicators of activity and progression in patients with highly active multiple sclerosis (HAMS) during the first year of therapy in real clinical practice.

Material And Methods: The study included 110 patients with HAMS and 13 patients with rapidly progressive MS (RPMS), aged 19 to 60 years, who received monoclonal antibody (MAT) therapy for 12 months. Group 1 consisted of 77 patients receiving NAT therapy, group 2 of 46 patients receiving OCR therapy.

[Evaluation of the quality of life in patients with ischemic heart disease].

The aim of this study was to analyze quality-of-life parameters in patients with coronary heart disease in Chelyabinsk region. The number of patients with coronary heart disease who took part in this research was 830 people. The data were collected with using of application form that was supplemented by the Russian-language questionnaire SF-36.